30 Dec 2012
Last updated during 18:56 ET
About 80 people in Scotland would be authorised for Kalydeco, also famous as ivacaftor
A new drug for people with a sold form of cystic fibrosis, accessible in England, contingency also be prescribed in Scotland, a gift has said.
NHS patients in England will be means to entrance Kalydeco, also famous as ivacaftor, from 1 January.
The Cystic Fibrosis Trust pronounced not appropriation a drug in Scotland would means “dismay and heartache”.
The trust pronounced it was confounded that people in Scotland were denied a potentially life-changing treatment.
Ed Owen, a trust’s arch executive, has created to a Scottish Medicines Consortium (SMC) on a day before a NHS in England starts to account it for all people over a age of 6 with a G551D cystic fibrosis mutation.
A preference by a SMC over a drug is approaching on 14 January, a gift said.
In his minute Mr Owen said: “We trust that a SMC will simulate delicately on a preference in England, and a rationale, before creation a preference on appropriation in Scotland.
“As a organization representing people with cystic fibrosis opposite a UK, a Cystic Fibrosis Trust would be perturbed and confounded during a conditions where people in Scotland were denied a potentially life-changing diagnosis openly accessible to those in England.
“Such an outcome would means substantial and unsuitable suspense for families opposite Scotland.”
The gift pronounced around 4% of patients opposite a UK have a G551D mutation, compared to around 11% of a Scottish cystic fibrosis population.
It pronounced this equates to about 80 people in Scotland who would be authorised for Kalydeco.